Evidence map›Paper›PMID 40507310›Full record

ArticleCancers2025

18F-FDG PET/CT Radiomics for Predicting Therapy Response in Primary Mediastinal B-Cell Lymphoma: A Bi-Centric Pilot Study.

Fabiana Esposito, Luigi Manco, Luca Urso, Sara Adamantiadis, Giovanni Scribano, Lucrezia De Marchi, Adriano Venditti, Massimiliano Postorino, Nicoletta Urbano, Roberta Gafà and 4 more

Abstract read
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Applications of artificial intelligence in nuclear medicine.Zeitschrift fur medizinische Physik · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Fabiana EspositoHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-7305-7222
Luigi MancoMedical Physics Unit, University Hospital of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy.ORCID 0000-0001-9338-8638
Luca UrsoDepartment of Translational Medicine, University of Ferrara, 44124 Ferrara, Italy.ORCID 0000-0002-3007-3898
Sara AdamantiadisDepartment of Translational Medicine, University of Ferrara, 44124 Ferrara, Italy.
Giovanni ScribanoMedical Physics Unit, University Hospital of Ferrara, Via Aldo Moro 8, 44124 Ferrara, Italy.ORCID 0009-0008-5391-3176
Lucrezia De MarchiHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0009-0009-3797-0741
Adriano VendittiHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-0245-0553
Massimiliano PostorinoHematology, Department of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.
Nicoletta UrbanoNuclear Medicine Unit, Department of Onco-Hematology, Fondazione PTV Policlinico Tor Vergata University Hospital, 00133 Rome, Italy.
Roberta GafàDepartment of Translational Medicine, University of Ferrara, 44124 Ferrara, Italy.ORCID 0000-0002-3271-2198
Antonio CuneoHematology Unit, University of Ferrara, 44121 Ferrara, Italy.ORCID 0000-0003-2001-1308
Agostino ChiaravallotiDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0002-8017-8858
Mirco BartolomeiNuclear Medicine Unit, Onco-Hematology Department, University Hospital of Ferrara, 44124 Ferrara, Italy.
Luca FilippiDepartment of Biomedicine and Prevention, University of Rome "Tor Vergata", 00133 Rome, Italy.ORCID 0000-0003-4423-5496

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis bi-centric pilot study investigates the predictive value of pre-treatment [

methodsAll PMBCL patients underwent PET/CT with [

resultsThe entire dataset was composed of 29 samples for the Rome cohort (23 from D1-D3 and 6 from D4/D5) and 9 samples for the Ferrara cohort (4 from D1-D3 and 5 from D4/D5). A total of 27 RFts were identified as robust for each imaging modality. Both the CT and PET models effectively predicted the Deauville score. The performance metrics of the best classifier (SVM) for the CT and PET models in external validation were AUC = 0.75/0.80, CA = 0.85/0.77, Prec = 0.97/0.67, Sen = 0.60/0.80, Spec = 0.98/0.75, TP = 75.0%/66.7%, and TN = 77.8%/85.7%, respectively.

conclusionsML models trained on [

Indexed as

18F-FDGartificial intelligencemachine learningPET/CTprimitive mediastinal B-cell lymphomaradiomics

Identifiers

PMID40507310
PMCPMC12153670

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.